iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

Earnings (Loss) Per Common Share (Tables)

3 Months Ended

Sep. 30, 2021

Earnings (Loss) Per Common Share [Abstract]

Schedule of Earnings (loss) Per Share, Basic and Diluted


		Three Months Ended
		September 30,
		2021			2020
Basic and diluted numerator:

Net loss attributable to iBio, Inc.		$	(8,939)		$	(7,533)
Preferred stock dividends – iBio CMO Preferred Tracking Stock			(66)			(66)
Deemed dividends – down round of Series A Preferred and Series B Preferred			—			—
Net loss available to iBio, Inc. stockholders		$	(9,005)		$	(7,599)

Basic and diluted denominator:

Weighted-average common shares outstanding			217,876			162,442

Per share amount		$	(0.04)		$	(0.05)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


		September 30,
		2021		2020

		(in thousands)
Stock options		14,400		3,486
Restricted stock units		769		41
Shares excluded from the calculation of diluted loss per share		15,169		3,527